Content and Format of INDs for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products Questions and Answers: Guidance for Industry Q&A
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
October 1, 2000
May 6, 2020
0b58e6c1-3ce5-461a-be2e-38697dc3a308
Related Documents
IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer: Guidance for Industry
Guidance DocumentJanuary 15, 2004Center for Drug Evaluation and Research
E11 Clinical Investigation of Medicinal Products in the Pediatric Population
Guidance DocumentDecember 15, 2000Center for Drug Evaluation and Research
Cancer Drug and Biological Products - Clinical Data in Marketing Applications
Guidance DocumentOctober 11, 2001Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox